The Non-steroidal Anti-inflammatory Drugs Market size was estimated at USD 20.29 billion in 2022 and expected to reach USD 21.71 billion in 2023, at a CAGR 7.46% to reach USD 36.10 billion by 2030.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Non-steroidal Anti-inflammatory Drugs Market.

  • Based on Disease Indication, market is studied across Arthritis, Migraine, and Ophthalmic Diseases. The Arthritis is projected to witness significant market share during forecast period.

  • Based on Drugs, market is studied across Over-the-counter Drugs and Prescription. The Over-the-counter Drugs is further studied across Aspirin (Bufferin, Bayer, & Excedrin), Ibuprofen (Advil, Motrin, Nuprin), Ketoprofen (Actron, Orudis), and Naproxen (Aleve). The Prescription is further studied across Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, and Voltaren. The Over-the-counter Drugs is projected to witness significant market share during forecast period.

  • Based on Route of Administration, market is studied across Oral and Parenteral. The Parenteral is projected to witness significant market share during forecast period.

  • Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Online Pharmacy is projected to witness significant market share during forecast period.

  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Non-steroidal Anti-inflammatory Drugs Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Non-steroidal Anti-inflammatory Drugs Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Non-steroidal Anti-inflammatory Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Assertio Therapeutics, Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline PLC, Iroko Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Perrigo Company PLC, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

The report offers valuable insights on the following aspects:

  1. Market Penetration: It provides comprehensive information about key players’ market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast for the Non-steroidal Anti-inflammatory Drugs Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Non-steroidal Anti-inflammatory Drugs Market?
  3. What is the competitive strategic window for identifying opportunities in the Non-steroidal Anti-inflammatory Drugs Market?
  4. What are the latest technology trends and regulatory frameworks in the Non-steroidal Anti-inflammatory Drugs Market?
  5. What is the market share of the leading vendors in the Non-steroidal Anti-inflammatory Drugs Market?
  6. Which modes and strategic moves are suitable for entering the Non-steroidal Anti-inflammatory Drugs Market?